News

Valneva and Pfizer Announce Positive Lyme Disease Vaccine Results

Valneva and Pfizer Announce Positive Lyme Disease Vaccine Results

Positive Phase 2 Results for Lyme Disease Vaccine Candidate

Valneva SE (NASDAQ: VALN; Euronext Paris: VLA) and Pfizer Inc. (NYSE: PFE) have announced encouraging outcomes from their Phase 2 study of the Lyme disease vaccine candidate, VLA15. The VLA15-221 study demonstrates a strong immune response just one month after administering a second booster dose to both children and adults. These results represent a crucial advancement in the fight against Lyme disease, which is becoming increasingly prevalent and impactful in various regions.

Immunogenicity and Safety Confirmed

The Phase 2 study showcased a remarkable anamnestic antibody response across all six OspA serotypes, consistent with earlier findings. Participants displayed a robust immune response, achieving seroconversion rates that exceeded 90% across all age groups, from children as young as 5 to adults up to 65 years old. The geometric mean titers remained high after both the initial and second booster doses, underscoring the vaccine’s dependability.

Strong Indicators of Efficacy

The timeline for developing the VLA15 vaccine is promising, progressing faster than any other Lyme disease vaccine candidate. With approximately 476,000 reported cases each year in the U.S. and over 129,000 cases in Europe, the demand for effective vaccination strategies is urgent. The results from the Phase 2 study further support the vaccine's potential as a preventive measure against Lyme disease, especially as the incidence of this illness continues to rise in endemic areas.

Insights from Company Leaders

Juan Carlos Jaramillo, M.D., Chief Medical Officer at Valneva, expressed his excitement about these findings. He remarked, “We are encouraged by these data, which support the potential benefit of booster doses across all examined age groups. As Lyme disease spreads, it represents a significant unmet medical need. Each new set of positive data brings us closer to potentially making this vaccine available for both adults and children.”

Safety Profile of VLA15

The evaluation of VLA15's safety and tolerability showed no significant issues reported by the independent Data Monitoring Committee. The safety profile remained favorable across all age groups for both the initial and booster doses, indicating strong potential for public acceptance of the vaccine.

Current and Future Research Directions

The partnership between Pfizer and Valneva includes several ongoing Phase 3 trials, such as the VALOR study, which aims to further evaluate the efficacy and safety of VLA15 among outdoor enthusiasts aged five and older. The primary vaccination series for these trials has been successfully completed, paving the way for subsequent booster assessments and data collection.

Valneva has established itself as a significant player in the vaccine sector, not only with VLA15 but also with a range of other vaccine candidates aimed at infectious diseases. Their ongoing commitment to Lyme disease highlights their dedication to addressing unmet medical needs in this area.

Understanding Lyme Disease and VLA15

Lyme disease is mainly caused by the bacterium Borrelia burgdorferi, which is transmitted through tick bites. Its symptoms are often misdiagnosed or confused with other illnesses, making effective vaccination essential as the geographical spread of Lyme disease continues to expand. VLA15, an investigational multivalent protein subunit vaccine, aims to combat the bacteria by targeting the outer surface protein A (OspA), contributing to improvements in public health.

Conclusion

In summary, the encouraging results from the Phase 2 study highlight the importance of VLA15 in combating Lyme disease. With ongoing research and diligent monitoring, Valneva and Pfizer are well-positioned to potentially transform preventive care for Lyme disease and other tick-borne illnesses.

Frequently Asked Questions

What are the main findings of the Phase 2 study for VLA15?

The Phase 2 study revealed a strong immune response and a favorable safety profile for VLA15 one month after the second booster dose.

What is VLA15 designed to protect against?

VLA15 is an investigational vaccine candidate aimed at preventing Lyme disease, specifically targeting the Borrelia burgdorferi bacteria responsible for the illness.

How does the vaccine work?

VLA15 functions by targeting the outer surface protein A (OspA) of the bacteria, which helps to inhibit its ability to infect humans through tick bites.

Why is this vaccine needed?

Currently, there are no approved vaccines for Lyme disease, yet it poses an increasing health threat with rising case numbers in both the U.S. and Europe.

What is the next step for VLA15?

Pfizer and Valneva are conducting ongoing Phase 3 clinical trials to further evaluate the vaccine's safety, efficacy, and immunogenicity across various age groups.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 41

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
Baidu's Q3 2026: AI Explodes Amid Marketing Slump

Updated Category News Views 59

Baidu Looks to AI as Revenue Driver in Q3 2026 You know, Baidu's got one heck of a story this quarter. Despite some clouds hanging over them, they’ve managed to find a silver lining in their AI ventures. It’s like they’ve got this magic bullet with AI Cloud growth skyrocketing 94% year over year. That’s not just a rabbit outta the hat; it’s more like pulling a...

Continue Reading
Sandals Foundation: Win a Trip, Boost Caribbean Education

Updated Category News Views 68

Sandals Resorts Stakes a Claim in Education While the rest of us are gravitating towards Black Friday deals and Cyber Monday sales, the Sandals Foundation decided to play a different game. This Giving Tuesday, they invite travelers not just to soak in the sun, but to spread a little of it around by supporting education for kids across the Caribbean. It's a classic example...

Continue Reading
FDA Changes Shake Up Medtech Inspections Landscape

Updated Category News Views 114

Inspecting the Changing FDA Landscape If you’ve been treating FDA inspections like a ride down memory lane, it's time for a wake-up call. What F. David Rothkopf plans to tell the medical device teams at the MEDevice Silicon Valley event is simple: the game has changed. The FDA’s Quality Management System Regulation (QMSR) that kicked in on February 2, 2026, isn’t...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 114

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
A&G Management's Bold New Era with WPM Partnership

Updated Category News Views 122

Shaking Up Baltimore's Real Estate Scene Swapping up management partners can be a dicey game, but A&G Management seems to be pulling it off without a hitch. As of January 4, 2027, WPM Real Estate Management will take over the reins for more than 3,000 apartment homes scattered across Anne Arundel, Howard, and Baltimore counties. A new set of hands is stepping in for...

Continue Reading
Lecanemab Shines in 5-Year Alzheimer's Study at CTAD

Updated Category News Views 71

Latest Lecanemab Results Turn Heads at CTAD 2026 The whispers buzzing out of the CTAD 2026 conference are about something promising for those in the trenches of Alzheimer's research: lecanemab. Yep, it's a name that's been bandied about before, and this time it's the long-term data doing the talking. The five-year results from Eisai and Biogen's lecanemab study are...

Continue Reading
Pinot's Palette Expands with New La Quinta Studio

Updated Category News Views 57

Canvas and Cabernet in Coachella Valley Grab your brushes and wine glasses; Pinot's Palette is branching out to La Quinta. As of November 27, locals and visitors alike can find their artistic flair at 47120 Dune Palms Road. This move isn’t just another business expansion—it's about blending community spirit with creativity, backed by the experienced entrepreneurs...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 247

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Charlotte's Top-Tier Home Sales Surge: A $15M Milestone

Updated Category News Views 95

Charlotte's Luxury Market: A Rapid Ascent Folks, buckle up, because the luxury home market in Charlotte isn't just on the rise—it's practically sky-high. Back in 2016, the idea of splashing out over $5 million on a house was almost unheard of in this neck of the woods. Only one brave soul did it at the time. Fast forward to this past year, and things are looking starkly...

Continue Reading

Top 5 Most Recently Viewed Articles

Sanoma Corporation's Recent Share Buyback Explained

Updated Category News Views 173

Insights into Sanoma Corporation's Share Buyback Activity Sanoma Corporation has conducted a significant share buyback, underscoring its commitment to enhancing shareholder value. These transactions were announced through a stock exchange release, giving investors an insightful look into the company's market activities. Details of the Buyback Transaction On a noteworthy...

Continue Reading
Finland's Real Estate Market Thrives in 2025: Key Insights

Updated Category News Views 248

The Resurgence of Finland's Real Estate Market Finland's real estate market is experiencing an inspiring recovery, marked by increasing transaction volumes and growing investment liquidity. This positive trend not only showcases renewed confidence among local investors but also reflects heightened interest from international players in the Finnish market. Analysts predict...

Continue Reading
Investors Alert: Join the Fight for Justice with aTyr Pharma

Updated Category News Views 190

Understanding the aTyr Pharma Situation Investors of aTyr Pharma Inc. are facing a challenging and distressing time following recent revelations regarding the company’s performance. The company is known for its innovative approaches in the realm of pharmaceuticals and has garnered significant attention in the stock market. However, the recent downturn in share value has...

Continue Reading
Fly Play hf. Reports Q2 Losses Amid External Challenges

Updated Category News Views 143

Profit Warning for Fly Play hf. Recently, Fly Play hf. shared concerns regarding its upcoming Q2 2025 interim financial report. The company anticipates that their results will fall short of last year’s performance and internal expectations. A net loss of around USD 16 million is projected for this quarter, compared to a loss of USD 10 million during the same period last...

Continue Reading
Olin Corporation Faces Challenges Amid Earnings Report

Updated Category News Views 85

Olin Corporation Reports Disappointing Third Quarter Earnings Olin Corporation (NYSE: OLN) recently announced its earnings for the third quarter of 2024, revealing significant challenges that led to a 14% drop in its stock price. This downturn was driven primarily by the fallout from Hurricane Beryl and a decline in demand within its ammunition division. Financial...

Continue Reading